Boston Scientific (NYSE:BSX) EVP Joseph Michael Fitzgerald Sells 50,000 Shares

Boston Scientific Corporation (NYSE:BSX) EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Joseph Michael Fitzgerald also recently made the following trade(s):

• On Tuesday, September 2nd, Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00.
• On Friday, August 1st, Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00.

Boston Scientific Stock Down 1.9%

NYSE BSX opened at $95.78 on Thursday. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The business’s fifty day simple moving average is $103.30 and its 200-day simple moving average is $102.08. The firm has a market cap of $141.91 billion, a PE ratio of 57.01, a P/E/G ratio of 2.35 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the firm earned $0.62 EPS. The company’s quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors have recently bought and sold shares of BSX. Norges Bank acquired a new position in shares of Boston Scientific during the second quarter worth about $2,089,937,000. Edgewood Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth about $746,655,000. Bessemer Group Inc. grew its position in shares of Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock worth $313,618,000 after buying an additional 2,899,653 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Boston Scientific by 1.9% during the second quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock worth $14,729,575,000 after buying an additional 2,545,381 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock worth $1,070,387,000 after buying an additional 1,664,108 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on BSX shares. Raymond James Financial raised their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Wells Fargo & Company raised their price objective on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. UBS Group raised their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday, July 24th. Needham & Company LLC reissued a “buy” rating and set a $121.00 price objective on shares of Boston Scientific in a research report on Wednesday. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 price objective on shares of Boston Scientific in a research report on Monday. Three analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $120.67.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.